Monica McNeal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207957/publications.pdf

Version: 2024-02-01

186265 197818 2,714 71 28 49 citations h-index g-index papers 74 74 74 2937 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	30.7	204
2	Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 981-989.	9.1	185
3	Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009–2011. Clinical Infectious Diseases, 2013, 57, 13-20.	5.8	146
4	Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production. Journal of Virology, 2011, 85, 753-764.	3.4	135
5	Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans. Journal of Infectious Diseases, 2012, 206, 1386-1393.	4.0	124
6	Epidemiologic Association Between <i>FUT2</i> Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatrics, 2015, 169, 1040.	6.2	112
7	Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 843-853.	9.1	109
8	Effector Role of Neonatal Hepatic CD8+ Lymphocytes in Epithelial Injury and Autoimmunity in Experimental Biliary Atresia. Gastroenterology, 2007, 133, 268-277.	1.3	103
9	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	9.1	103
10	Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012–2013. Clinical Infectious Diseases, 2015, 61, 1792-1799.	5.8	78
11	Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics, 2021, 148, .	2.1	72
12	Effect of Rotavirus Strain on the Murine Model of Biliary Atresia. Journal of Virology, 2007, 81, 1671-1679.	3.4	68
13	Simian Rotaviruses Possess Divergent Gene Constellations That Originated from Interspecies Transmission and Reassortment. Journal of Virology, 2010, 84, 2013-2026.	3.4	60
14	Seroepidemiologic Evaluation of Antibodies to Rotavirus as Correlates of the Risk of Clinically Significant Rotavirus Diarrhea in Rural Bangladesh. Journal of Infectious Diseases, 1992, 165, 161-165.	4.0	57
15	A candidate dual vaccine against influenza and noroviruses. Vaccine, 2011, 29, 7670-7677.	3.8	57
16	Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2020, 20, 851-863.	9.1	51
17	Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Vaccine, 2015, 33, 3766-3772.	3.8	48
18	Enterovirus D68–Associated Acute Respiratory Illness — New Vaccine Surveillance Network, United States, July–October, 2017 and 2018. Morbidity and Mortality Weekly Report, 2019, 68, 277-280.	15.1	48

#	Article	IF	Citations
19	Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis. Emerging Infectious Diseases, 2013, 19, 1245-1252.	4.3	46
20	Cholangiocyte expression of $\hat{l}\pm \langle sub \rangle 2 \langle sub \rangle \hat{l}^2 \langle sub \rangle 1 \langle sub \rangle$ -integrin confers susceptibility to rotavirus-induced experimental biliary atresia. American Journal of Physiology - Renal Physiology, 2008, 295, G16-G26.	3.4	44
21	Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1686-1693.	4.0	44
22	Impact of Different Dosing Schedules on the Immunogenicity of the Human Rotavirus Vaccine in Infants in Pakistan: A Randomized Trial. Journal of Infectious Diseases, 2014, 210, 1772-1779.	4.0	41
23	The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine, 2010, 28, 3748-3753.	3.8	37
24	Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine, 2021, 39, 101076.	7.1	37
25	Rotavirus infection of human cholangiocytes parallels the murine model of biliary atresia. Journal of Surgical Research, 2012, 177, 275-281.	1.6	33
26	The Rhesus Rotavirus Gene Encoding VP4 Is a Major Determinant in the Pathogenesis of Biliary Atresia in Newborn Mice. Journal of Virology, 2011, 85, 9069-9077.	3.4	32
27	Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells. Journal of Clinical Investigation, 2019, 129, 3839-3851.	8.2	32
28	MAPK signaling contributes to rotaviral-induced cholangiocyte injury and viral replication. Surgery, 2007, 142, 192-201.	1.9	31
29	A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine, 2018, 36, 4880-4889.	3.8	30
30	Rotavirus Replication in the Cholangiocyte Mediates the Temporal Dependence of Murine Biliary Atresia. PLoS ONE, 2013, 8, e69069.	2.5	29
31	Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics, 2016, 137, e20152603.	2.1	28
32	INCIDENCE OF INFLUENZA VIRUS INFECTION IN EARLY INFANCY. Pediatric Infectious Disease Journal, 2011, 30, 170-173.	2.0	27
33	Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	25
34	Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2. Pediatric Neurology, 2022, 127, 1-5.	2.1	24
35	Norovirus P Particle as a Platform for Antigen Presentation. Procedia in Vaccinology, 2011, 4, 19-26.	0.4	23
36	Vaccine Effectiveness Against Pediatric Influenza Hospitalizations and Emergency Visits. Pediatrics, 2020, 146, e20201368.	2.1	21

#	Article	IF	CITATIONS
37	High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants. Hepatology, 2021, 74, 864-878.	7.3	20
38	Multiplex real-time RT-PCR for the simultaneous detection and quantification of GI, GII and GIV noroviruses. Journal of Virological Methods, 2015, 223, 109-114.	2.1	19
39	Vaccine Effectiveness Against Influenza Hospitalization Among Children in the United States, 2015–2016. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 75-82.	1.3	19
40	Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Human Vaccines and Immunotherapeutics, 2021, 17, 554-559.	3.3	19
41	Estimating the Rotavirus Hospitalization Disease Burden and Trends, Using Capture-recapture Methods. Pediatric Infectious Disease Journal, 2010, 29, 1083-1087.	2.0	18
42	Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials, 2014, 35, 8427-8438.	11.4	18
43	Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. JAMA Network Open, 2019, 2, e1912242.	5.9	18
44	Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine, 2021, 39, 5513-5523.	3.8	16
45	Enterovirus D68 Infection Among Children With Medically Attended Acute Respiratory Illness, Cincinnati, Ohio, July–October 2014. Clinical Infectious Diseases, 2017, 65, 315-323.	5.8	15
46	Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. Vaccine, 2018, 36, 4663-4671.	3.8	15
47	Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B∣Victoria Viruses, 2019–2020. Clinical Infectious Diseases, 2021, 73, e947-e954.	5.8	15
48	Rhesus rotavirus VP4 sequence-specific activation of mononuclear cells is associated with cholangiopathy in murine biliary atresia. American Journal of Physiology - Renal Physiology, 2015, 309, G466-G474.	3.4	14
49	The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia. Hepatology, 2017, 65, 1278-1292.	7.3	13
50	Cytomegalovirus Genetic Diversity Following Primary Infection. Journal of Infectious Diseases, 2020, 221, 715-720.	4.0	13
51	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	13
52	Rotavirus Reassortant–Induced Murine Model of Liver Fibrosis Parallels Human Biliary Atresia. Hepatology, 2020, 71, 1316-1330.	7.3	12
53	Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial. PLoS Medicine, 2021, 18, e1003720.	8.4	12
54	Rhesus rotavirus VP6 regulates ERK-dependent calcium influx in cholangiocytes. Virology, 2016, 499, 185-195.	2.4	11

#	Article	IF	Citations
55	A Point Mutation in the Rhesus Rotavirus VP4 Protein Generated through a Rotavirus Reverse Genetics System Attenuates Biliary Atresia in the Murine Model. Journal of Virology, 2017, 91, .	3.4	11
56	Pediatric Respiratory and Enteric Virus Acquisition and Immunogenesis in US Mothers and Children Aged 0-2: PREVAIL Cohort Study. JMIR Research Protocols, 2021, 10, e22222.	1.0	11
57	Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial. PLoS Medicine, 2021, 18, e1003655.	8.4	10
58	Continued Evidence of the Impact of Rotavirus Vaccine in Children Less Than 3 Years of Age From the United States New Vaccine Surveillance Network: A Multisite Active Surveillance Program, 2006–2016. Clinical Infectious Diseases, 2020, 71, e421-e429.	5.8	8
59	Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 82-85.	1.3	7
60	Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Oldâ€"New Vaccine Surveillance Network 2016â€"2017 and 2017â€"2018. Journal of Infectious Diseases, 2022, 226, 91-96.	4.0	6
61	T-Bet Deficiency Attenuates Bile Duct Injury in Experimental Biliary Atresia. Cells, 2021, 10, 3461.	4.1	6
62	Role of myeloid differentiation factor 88 in Rhesus rotavirus-induced biliary atresia. Journal of Surgical Research, 2013, 184, 322-329.	1.6	5
63	Ultrastructure of cultured hepatocytes from fat- and cholesterol-fed rats. Vigiliae Christianae, 1982, 41, 95-106.	0.1	4
64	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2.5	4
65	Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. PLoS ONE, 2021, 16, e0259361.	2.5	4
66	Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial. Journal of Infectious Diseases, 2022, , .	4.0	4
67	Rotaviruses. , 2014, , 713-732.		3
68	Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015–2016. Influenza and Other Respiratory Viruses, 2022, 16, 289-297.	3.4	3
69	Persistence of Maternal Anti-Rotavirus Immunoglobulin G in the Post–Rotavirus Vaccine Era. Journal of Infectious Diseases, 2021, 224, 133-136.	4.0	2
70	Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants. Vaccine, 2022, 40, 3444-3451.	3.8	1
71	Rotavirus. , 2009, , 645-669.		0